Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7.
We report 14 cases of secondary myelodysplastic syndromes (sMDS) following treatment with azathioprine for non-malignant disorders. Long-term treatment with azathioprine seems to be associated with an increased risk of MDS and subsequent leukemic transformation.
Knipp
Sabine
S
Hildebrandt
Barbara
B
Richter
Jutta
J
Haas
Rainer
R
Germing
Ulrich
U
Gattermann
Norbert
N
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001327:Autoimmune Diseases / Q000188:drug therapy; D001379:Azathioprine / Q000009:adverse effects* / Q000627:therapeutic use; D002471:Cell Transformation, Neoplastic / Q000139:chemically induced; D002897:Chromosomes, Human, Pair 7 / Q000648:ultrastructure*; D005260:Female; D016027:Heart Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D017404:In Situ Hybridization, Fluorescence; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D009006:Monosomy; D009190:Myelodysplastic Syndromes / Q000139:chemically induced* / Q000235:genetics; D011183:Postoperative Complications / Q000139:chemically induced; D012189:Retrospective Studies; D012216:Rheumatic Diseases / Q000188:drug therapy; D014178:Translocation, Genetic
D007166:Immunosuppressive Agents; D001379:Azathioprine